SCHEMBL5137422

SCHEMBL5137422

CCCCCCCCN(Cc1ccc2c(c1)OCO2)Cc1cnc(-c2ccc(F)cc2)n1CCCC

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
F2R P25116 1/20 0.41
HSP90AA1 P07900 2/20 0.40
HSP90AB1 P08238 2/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTSL P07711 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5254031 1.00 C5AR1 (0.47) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5201029 1.00 C5AR1 (0.47) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5216956 0.99 C5AR1 (0.48) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5149996 0.96 C5AR1 (0.49) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL4766728 0.94 C5AR1 (0.51) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5136744 0.93 C5AR1 (0.47) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5135843 0.92 C5AR1 (0.45) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5137592 0.91 C5AR1 (0.57) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5136211 0.91 C5AR1 (0.57) C5AR1F2RHSP90AA1HSP90AB1HTR2A
SCHEMBL5135017 0.91 C5AR1 (0.57) C5AR1F2RHSP90AA1HSP90AB1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed